Drug Profile
Terbinafine hydrochloride - Blueberry Therapeutics
Alternative Names: BB-2603; Terbinafine nanoLatest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator Blueberry Therapeutics
- Class Amines; Antifungals; Naphthalenes; Peptide aptamers; Skin disorder therapies; Small molecules
- Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Onychomycosis
- Phase I/II Tinea pedis
Most Recent Events
- 13 Nov 2023 Efficacy and adverse events data from a phase II trial in Onychomycosis released by Blueberry Therapeutics
- 28 Jun 2023 Blueberry Therapeutics completes a phase II trial for Onychomycosis (In adults, In the elderly) in Czech Republic, Germany and Poland in March 2021 (Topical) (NCT04188574)
- 17 Feb 2021 Phase-II clinical trials in Onychomycosis in Poland, Germany, Czech Republic (Topical) (NCT04188574), (EudraCT2019-002098-68)